We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Poolbeg Pharma Plc | LSE:POLB | London | Ordinary Share | GB00BKPG7Z60 | ORD 0.02P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.45 | -8.04% | 5.15 | 3,897,651 | 16:09:48 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 5.00 | 5.30 | 5.75 | 5.15 | 5.60 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | -3.93M | -0.0079 | -6.52 | 28M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:16:47 | O | 1,000,000 | 5.075 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 10/1/2025 | 16:07 | ALNC |  IN BRIEF: Poolbeg Pharma notes Gilead interest in Hookipa fundraise |
| 10/1/2025 | 11:48 | UK RNS | Cavendish Securities PLC Form 8.5 (EPT/NON-RI) |
| 10/1/2025 | 10:47 | UK RNS | J & E Davy (UK) Limited Form 8.5 (EPT/NON-RI) |
| 10/1/2025 | 07:00 | UK RNS | Poolbeg Pharma PLC Update Potential Combination of Poolbeg & HOOKIPA |
| 09/1/2025 | 16:28 | UK RNS | J & E Davy Unlimited Company Form 8.5- Poolbeg Pharma PLC |
| 09/1/2025 | 08:53 | UK RNS | Cavendish Securities PLC Form 8.5 (EPT/NON-RI) |
| 09/1/2025 | 07:00 | UK RNS | Poolbeg Pharma PLC Holding(s) in Company |
| 08/1/2025 | 15:56 | UK RNS | J & E Davy Form 8.5 (EPT/NON-RI) - Poolbeg Pharma PLC |
| 08/1/2025 | 15:53 | UK RNS | Poolbeg Pharma PLC Form 8 (OPD) - Poolbeg Pharma plc |
| 08/1/2025 | 09:44 | UK RNS | Cavendish Securities PLC Form 8.5 (EPT/NON-RI) |
Poolbeg Pharma (POLB) Share Charts1 Year Poolbeg Pharma Chart |
|
1 Month Poolbeg Pharma Chart |
Intraday Poolbeg Pharma Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 10/1/2025 | 19:03 | Poolbeg Pharma | 3,985 |
| 24/10/2022 | 15:20 | Polb | 1 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 11/1/2025 08:20 by Poolbeg Pharma Daily Update Poolbeg Pharma Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker POLB. The last closing price for Poolbeg Pharma was 5.60p.Poolbeg Pharma currently has 500,000,000 shares in issue. The market capitalisation of Poolbeg Pharma is £25,750,000. Poolbeg Pharma has a price to earnings ratio (PE ratio) of -6.52. This morning POLB shares opened at 5.60p |
Posted at 10/1/2025 13:55 by burtond1 Seems a little confusion around this deal for @PoolbegPharma ?For what it's worth, here is my take....I see some peoples strategy is to sell #POLB and buy Hookipa to get the CVR. This is an obvious strategy BUT in my opinion a potentially dangerous one!! Hookipa is loss making, though it is clear that with the Poolbeg influence they are doing a massive headcount reduction. No way Hookipa could raise the 30m fundraise PIPE without the Poolbeg team and the Poolbeg deal on the table. If the Poolbeg deal doesn't go ahead then Hookipa share price is likely to drop considerably lower than where it is now. With me so far??! Poolbeg have shown that they're very effective at running their capital light model still having £10.1m cash 3 years post IPO and the management team have turned around loss making companies before like hVIVO. I think the best route would to be not overly risky and simply wait a few weeks and invest in the $30m fundraise as a I expect most existing Poolbeg shareholders would be offered the possibility to participate. By doing it this way, you are not exposed to the risk of the deal going ahead or not and you still see the benefits of 45% of the $400m+ milestone payments which stay with the combined company.#Simples |
Posted at 10/1/2025 09:32 by pogue Re the reason for the rise here see link below. I have now confirmed to myself Peterrr3 is a deramper. The information is obvious for him not to work it out after all his posting about looking into POLB and advising they were looking for a fundraise.A two second google on Gilead drugs and you goto the cancer ones, obviously, and you see 2 have CRS as a side effect. Clearly Gilead were one of the companies talking to POLB re doing trials with their drugs and POLB. So now late this year Phase 2 of POLB001 will go ahead. If you struggle to find info on the trial date try reading this presentation, again not hard to find the info if you do any research page 30 has the clinical milestones chart. |
Posted at 09/1/2025 21:43 by troutisout I always worked on POLB being half the price of HVO and it was roughly that for a long while, up until last year when HVO outperformed that, POLB once got back to half the value but suffered far more last year then HVO and even now the drop for POLB was far more than HVO has suffered, in fact POLB is less than a third of the HVO price, but your hatred for one and love for another abounds.....Are you CF in disguise?free stock charts from uk.advfn.com free stock charts from uk.advfn.com free stock charts from uk.advfn.com |
Posted at 03/1/2025 13:14 by toby hall a post from the other sideDingodog1 ..Today 13:03 My take is that HOOK is an appropriate "vessel" that POLB can use to access NASDAQ. It is sufficiently "distressed" that POLB can get a sizeable level of equity (even post dilution) to allow a tangiable return if should POLB take off. Arguably POLB001 is the golden ticket from POLB's perspective, and bolting on to HOOK effectively gives POLB access to the capital markets of the US, which may value it more favourably. Yes HOOK may be coming along for the ride as the vessel, but i wouldnt be too focused on what HOOK brings to the table other than the vessel it provides. AIM values POLB at, say, £40m. Nasdaq MAY value it at £400m+. That is a ten bag, albeit diluted to incorporate HOOK and the fund raise. My view is that Cathal is looking at future value, not immediate value. Many on here have said before that AIM is a cesspit etc and thus the value for POLB may not be truly recognised. Taking POLB to the nasdaq via HOOK MAY unlock that value. IF the new group is valued at £400m on nasdaq i dont think anyone will complain. As i say, i think HOOK is the vessel, not the perfect partner for us to tap into their offerings. How much would it cost to float POLB on nasdaq? Is that even possible? How long would it take? I think this route is considered to accelerate proceesings whilst recognising value. All imo, and the silence of the BOD and CF doesnt help |
Posted at 02/1/2025 17:01 by sikhthetech The newsflow here has been as expectedsikhthetech - 03 Apr 2022 - 14:23:15 - 592 of 3844 Poolbeg Pharma - POLB 1gw "And just to come back on sikhthetech's misunderstanding" No misunderstanding on my part, you're misleading readers re dual listings. We both have seen companies move to US dual/fully listed.. Trmr, sln, pic, summ and I have also experienced Signet and Ceva move to US listing. The topic was dual listing for Polb and what might happen. Yet you (deliberately I would say) didn't mention companies who have dual listed. I've mentioned them, TRMR, SLN and yet you still won't answer the questions: How have trmr & sln fared since they dual listed. How have PIs, ie sp, fared since they dual listed. So be honest for once and state what happened in these 2 cases after they dual listed? Why are you trying to hide the truth? Obviously the share price rose pre-dual listing as it's selling PIs a good story without telling them the reality. ;-) |
Posted at 09/12/2024 07:25 by burtond1 Good morning,I hope all is well and please see link to RNS Reach issued by Poolbeg this morning: https://www.londonst |
Posted at 13/10/2024 08:54 by pogue Peterrr3I go to plenty events to window shop, going to an event does not mean there is a fundraise going to happen, I suggest you are taking one presentation out of context and extrapolating to the moon. I don’t see where they need the funds to be honest. They started out 3 years ago with around £20 million and now have around £10 million and are trailing POLB001 with 2 pharma companies’ drugs which suggests they are in advanced talks as if they goto human trial, they have done the In Vivo animal trial, there would have to be a contract signed setting out the partnership/selling deal should the result be positive as is normal in these situations in industry. No pharma company would want to increase the value of a 3rd party drug by proving it successful without having a price fixed beforehand. Why fundraise when you are that close to a massive monetisation of your lead asset? Why are they trying to find an orphan drug to sell? Well to make money perhaps? POLB have a pipeline of drugs they develop and sell/partner. Pentoxifylline has past phase II so they don’t need to put it through a trial. I don’t know what the deal will be with the owner but I cannot see POLB buying it unless they have a buyer. I suggest the most likely is a partnership where POLB help sell the drug and share in the profits. This is a capital light company they don’t spend money unless they have to bringing on drugs, have you seen the very small quantities of cash they have spent on the existing drugs in the pipeline? The fact they have spent only £10 million or so over 3 years is a clue. As I said I have listened to the Liam Trimble go on about POLB’s encapsulation tech being used in a trail later this year all 43 seconds off it and did not get excited about at the time as an oral encapsulation trial was being planned from the beginning of this year and was initially down to happen July/August so not seeing what the issue is, nothing new in it. The cost will be small and is being tested for use with another company’s drug they will contribute in some way same as those pharmas running the POLB001 trials did. The trial is very simple for encapsulation. Volunteer comes into medical establishment, pops a pill come backs next day to get a blood test to see if the drug has dispersed in their system, you really think they need a fundraise for this and it hasn’t been planned for? It is not the drug that’s being tested its oral encapsulation so not dangerous or expensive do you really think a sudden fundraise is needed for that as it has been planned for for a long time? As I said POLB does not have an obesity drug it’s the encapsulation that is being trailed. Should the trial work then there is a vast market out there for oral encapsulation way outside obesity drugs. Really cant see what you are going on about there. So to summarise why do you think they need a fundraise when they are getting close to a deal on POLB001? Oral encapsulation has been planned for trial for a long time and is not expensive to do. Pentoxifylline does not belong to POLB, they have an option on it and is past phase II so what cash do they need to spend as the option will more than likely be on a deal to sell in partnership with current owner and they dont need to conclude the deal if they see no buyers. |
Posted at 18/9/2024 10:14 by pogue My typing was a bit rushed had a meeting to prep so my post should have read 'I assume you are not invested'.Anyway sugar coating are what CEOs are paid to do. If you want real info and are good at talking, I suggest going to an event and speaking to CEOs I do it regularly, am going to one tomorrow night, and you can get amazing information from how they answer a question if set correctly. Its an artform kind of like interrogation. Lots can be deduced from tone, body language and avoidance of points. In the case of POLB I see massive positives which I highlighted and these are in the short term. Highlighting minor negatives further down the pipeline is pointless as the company's share price will be decided on POLB001 and encapsulation in the short term and both are moving forward, I expect POLB001 to have the in human trials with cancer drugs soon and encapsulation should be up for sale/partnering in the New Year after human trials. If you are investing these are the points to focus on as those are what will give the share price a massive lift. If you are not invested then looking at the negatives and trying to spin them out as massive problems is what you do but you wont make money that way. |
Posted at 02/7/2024 11:38 by pogue peterr3I will spell it out as I feel you were listening to the wrong bits there. The lead asset of POLB is POLB001 and will be the first monetized. 2 pharmas are interested in it as their new very powerful cancer drugs have the side effect of cytokine storms. Cytokline storms mean that patients tie up hospital beds in cancer units thus reducing the amount of drugs that can be administered so huge incentive to find a drug that prevents them happening, like POLB001. Hugh incentive there for a phamra to partner with POLB if POLB001 works. Now as a stand alone drug POLB001 does the job all they have to do is prove it works whilst other drugs are in a patients system. The 2 pharmas have already given POLB the drugs, worth £millions, to run the trial and will pay for the trial as the market for their drug is 10s of $billions. We await the trial date how long do you think the pharmas are going to wait with a prize of that size? Now the other part you need to research is what normally happens in these situations ie a drug going to trial with another and what the trial contract normally says baring in mind that if it proves successful the value of POLB001 goes through the roof. Clue the contract has a section on that and I strongly suggest that is the reason for the delay as its a very important section.. Sorry if very direct but you have missed the point completely of what is happening and this board has so many halfwit derampers who avoid basic facts that I treat posters I dont know with suspicion. |
Posted at 07/5/2024 21:47 by elrico Sicko, It's unjust to judge others by your own standards. I consistently reveal my sale/top slice a minimum of two trading days in advance if I possess a stated position. Additionally, not everyone can dedicate hundreds of hours each month; some have demanding careers, families, etc. Nevertheless, I do concur that whenever feasible, investors ought to DTOR, such as reviewing independent analyses. You might label these individuals as "cheerleaders" to fit your narrative. Relying on your analyses could have been risky with HVO and POLB, yet one thing is certain, you have been consistently inaccurate.I recall you singing the pump & dump song when POLB share price was c6p. Had anyone been put off by your constant trashing, they would have missed out on healthy gains. I do hope you are pleased with yourself. Instead of just highlighting investors' losses, why not provide some balance by sharing your own? As flawless as you may seem compared to Buffet and Munger, I'm fairly certain you've also had your fair share of failed investments. I know I have over the past 30+ years. Play nice! |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
